Referencia número: HY-109015

Tucidinostat

(Synonyms: Chidamide; HBI-8000; CS 055)

36 Cited Publications

Revisión del cliente

Based on 36 publication(s) in Google Scholar

Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC₅₀s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.74%
No. CAS: 1616493-44-7
Fòrmula: C₂₂H₁₉FN₄O₂
Peso molecular:390.41

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tucidinostat Chemical Structure

No. CAS: 1616493-44-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (36)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]

HDAC3

67 nM (IC₅₀)

HDAC10

78 nM (IC₅₀)

HDAC1

95 nM (IC₅₀)

HDAC2

160 nM (IC₅₀)

HDAC11

432 nM (IC₅₀)

HDAC8

733 nM (IC₅₀)

Ver todos los productos específicos de isoformas HDAC :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	0.63 μM Compound: chidamide	Antiproliferative activity against human 786-O cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human 786-O cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
A549	IC₅₀	2.79 μM Compound: chidamide	Antiproliferative activity against human A549 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human A549 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
A549	IC₅₀	9432 nM Compound: 5	Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
A549	IC₅₀	9.85 μM Compound: 6; CS005	Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
CAKI-1	IC₅₀	570 nM Compound: 5	Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAKI-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
CCRF-CEM	IC₅₀	0.63 μM Compound: Chidamide	Cytotoxicity against human CCRF-CEM cells by MTT assay Cytotoxicity against human CCRF-CEM cells by MTT assay	[PMID: 31078410]
CCRF-CEM	IC₅₀	0.83 μM Compound: chidamide	Antiproliferative activity against human CCRF-CEM cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human CCRF-CEM cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
CCRF-CEM	IC₅₀	1 μM Compound: Chidamide	Cytotoxicity against human CCRF-CEM cells measured after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells measured after 72 hrs by MTT assay	[PMID: 34986303]
COLO-678	IC₅₀	>10 μM Compound: chidamide	Antiproliferative activity against human COLO-678 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human COLO-678 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
CWR22R	IC₅₀	1.08 μM Compound: chidamide	Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
DOHH-2	IC₅₀	0.53 μM Compound: chidamide	Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
DOHH-2	IC₅₀	449 nM Compound: 5	Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human DOHH-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
DU-145	IC₅₀	1.49 μM Compound: 6; CS005	Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
EBC-1	IC₅₀	2.9 μM Compound: CS-055	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	[PMID: 28835797]
ES-2	IC₅₀	669 nM Compound: 5	Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ES2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	7.8 μM Compound: CS-055	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 28835797]
HCT-116	IC₅₀	1.09 μM Compound: HBI-8000; CS055	Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
HCT-116	IC₅₀	>20 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HCT116 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HCT-116	IC₅₀	0.34 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HCT-116	IC₅₀	2.08 μM Compound: chidamide	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
HCT-116	IC₅₀	2.082 μM Compound: Chidamide	Antiproliferative activity against human HCT-116 cells assessed as cell viability at 1 uM incubated for 72 hrs by luminescence assay Antiproliferative activity against human HCT-116 cells assessed as cell viability at 1 uM incubated for 72 hrs by luminescence assay	[PMID: 34995925]
HCT-116	IC₅₀	2.08 μM Compound: Chidamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
HCT-116	IC₅₀	1.18 μM Compound: 5	Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HCT-116	IC₅₀	0.92 μM Compound: 6; CS005	Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HEK293	IC₅₀	6244 nM Compound: 5	Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HEK293 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HEL	IC₅₀	0.013 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HEL cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HEL cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HEL	IC₅₀	1.8 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HEL cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HEL cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HeLa	IC₅₀	2623 nM Compound: 5	Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
HeLa	IC₅₀	7.16 μM Compound: CS055, Epidaza	Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay Inhibition of HDAC in human HeLa cell extract incubated for 1 hr by colorimetric activity assay	10.1039/C4MD00350K
HepG2	IC₅₀	4.89 μM Compound: 2	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
HepG2	IC₅₀	2 μM Compound: Chidamide	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
HL-60	IC₅₀	1.97 μM Compound: HBI-8000; CS055	Antiproliferative activity against human HL60 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human HL60 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
HL-60	IC₅₀	0.0022 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HL-60	IC₅₀	3.2 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human HL60 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
HL-60	IC₅₀	3.11 μM Compound: Chidamide	Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
HT-29	IC₅₀	6.04 μM Compound: chidamide	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
HT-29	IC₅₀	4.57 μM Compound: 6; CS005	Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
HuT78	IC₅₀	2.42 μM Compound: chidamide	Antiproliferative activity against human HuT78 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human HuT78 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
Jurkat	IC₅₀	1202 nM Compound: 5	Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
K562	IC₅₀	0.747 μM Compound: HBI-8000; CS055	Antiproliferative activity against human K562 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human K562 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
K562	IC₅₀	0.87 μM Compound: 2	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
K562	IC₅₀	1.34 μM Compound: Chidamide	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 31078410]
K562	IC₅₀	0.32 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
K562	IC₅₀	2.4 μM Compound: 1; CS055, HBI-8000	Antiproliferative activity against human K562 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 31938461]
K562	IC₅₀	8.3 μM Compound: Chidamide	Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 34986303]
K562	IC₅₀	1775 nM Compound: 5	Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
Kasumi 1	IC₅₀	>10 μM Compound: Chidamide	Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
LNCaP	IC₅₀	2.89 μM Compound: 6; CS005	Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay Antiproliferative activity against human LNCaP cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MC-38	IC₅₀	3.3 μM Compound: 5	Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse MC38 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MCF7	IC₅₀	29.07 μM Compound: HBI-8000; CS055	Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method	[PMID: 30802729]
MCF7	IC₅₀	>20 μM Compound: 6; CS005	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-231	IC₅₀	9.52 μM Compound: chidamide	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
MDA-MB-231	IC₅₀	619 nM Compound: 5	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MDA-MB-231	IC₅₀	1.86 μM Compound: 6; CS005	Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
MDA-MB-468	IC₅₀	2.65 μM Compound: 2	Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
MIA PaCa-2	IC₅₀	1682 nM Compound: 5	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
MOLT-4	IC₅₀	0.75 μM Compound: chidamide	Antiproliferative activity against human MOLT-4 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human MOLT-4 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
MV4-11	IC₅₀	3.73 μM Compound: 2	Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay	[PMID: 31053508]
MV4-11	IC₅₀	0.783 μM Compound: Chidamide	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis	[PMID: 35649291]
NCI-H1650	IC₅₀	>20 μM Compound: 6; CS005	Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H441	IC₅₀	2.62 μM Compound: chidamide	Antiproliferative activity against human NCI-H441 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human NCI-H441 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
NCI-H446	IC₅₀	0.24 μM Compound: 6; CS005	Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
NCI-H460	IC₅₀	2.34 μM Compound: chidamide	Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
NCI-N87	IC₅₀	4515 nM Compound: 5	Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-N87 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	3091 nM Compound: 5	Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-3 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
PC-3	IC₅₀	5.77 μM Compound: 6; CS005	Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay Antiproliferative activity against human PC-3 cells incubated for 96 hrs by MTT assay	[PMID: 38503167]
PC-9	IC₅₀	1714 nM Compound: 5	Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]
Rec1	IC₅₀	1.01 μM Compound: chidamide	Antiproliferative activity against human REC1 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human REC1 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
RS4-11	IC₅₀	0.6 μM Compound: chidamide	Antiproliferative activity against human RS4-11 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human RS4-11 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
Sf9	IC₅₀	0.167 μM Compound: 2	Inhibition of recombinant full-length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay Inhibition of recombinant full-length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay	[PMID: 31053508]
SKM-1	IC₅₀	549 nM Compound: CS055	Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay	[PMID: 37184921]
SK-OV-3	IC₅₀	8.46 μM Compound: chidamide	Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
SU-DHL-2	IC₅₀	0.56 μM Compound: chidamide	Antiproliferative activity against human SUDHL2 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human SUDHL2 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
TMD8	IC₅₀	0.48 μM Compound: chidamide	Antiproliferative activity against human TMD8 cells incubated for 72 hrs by luminescence assay Antiproliferative activity against human TMD8 cells incubated for 72 hrs by luminescence assay	[PMID: 34954594]
U-937	IC₅₀	3.3 μM Compound: Chidamide	Cytotoxicity against human U-937 cells measured after 72 hrs by MTT assay Cytotoxicity against human U-937 cells measured after 72 hrs by MTT assay	[PMID: 34986303]
U-937	IC₅₀	4.66 μM Compound: Chidamide	Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
ZR-75-1	IC₅₀	>10000 nM Compound: 5	Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction of cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36934335]

In Vitro

Tucidinostat (Chidamide/CS055/HBI-8000) is a potent and orally bioavailable HDAC enzymes class I (HDAC1, 2, 3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC₅₀s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9 (IC₅₀s, >30 μM). Tucidinostat shows potent antitumor activity, and inhibits several human derived tumor cell lines, such as HL-60, U2OS, LNCaP with GI₅₀s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tucidinostat (12.5-50 mg/kg, p.o.) dose-dependently reduces tumor size and tumor weight in mice bearing HCT-8 colorectal carcinoma, A549 lung carcinoma, BEL-7402 liver carcinoma, and MCF-7 breast carcinoma, and with no obvious body loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 1616493-44-7
Appearance Solid
Peso molecular 390.41
Fòrmula C₂₂H₁₉FN₄O₂
Color White to off-white
SMILES

O=C(C1=CC=C(CNC(/C=C/C2=CN=CC=C2)=O)C=C1)NC(C=CC(F)=C3)=C3N
Synonyms

Chidamide; HBI-8000; CS 055
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (36)

All WBIPCell Proliferation/Viability AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nat Commun

YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. [Abstract]

2023 Sep 22;14(1):5916. PMID: 37739954

Tucidinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 22;14(1):5916. [Abstract]

Tucidinostat (1 μM; 24 h). Benzamide HDAC inhibitors induce YAP protein in H209 and H69 cells.
Exp Hematol Oncol

IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response. [Abstract]

2025 Feb 15;14(1):15. PMID: 39955584
J Adv Res

Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS/MAPK pathway inhibitors in KRAS-mutant cancers. [Abstract]

2026 Feb 13:S2090-1232(26)00144-X. PMID: 41692243
Adv Sci (Weinh)

HDAC2-Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple-Negative Breast Cancer. [Abstract]

2025 Apr;12(14):e2413121. PMID: 39950833

Tucidinostat purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2413121. [Abstract]

IP analysis of MB231 cells treated with HDAC2 inhibitor Tucidinostat (1 µM; 72 h) .

Tucidinostat purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2413121. [Abstract]

Cisplatin dose–response curves for MB231 cells infected with HDAC2 shRNA or treated with Tucidinostat (0.5 µM; 72 h) as detected by CCK‐8 assay.

Tucidinostat purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2413121. [Abstract]

Cisplatin dose–response for clonogenic assay and quantification of MB231 subjected to HDAC2 shRNA or 0.5 µM Tucidinostat administration for 14 days.

Tucidinostat purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2413121. [Abstract]

Representative images of γH2AX foci in MB231 subjected to 0.5 µM Tucidinostat administration or/and 1 µM cisplatin treatment for 24 h.
Cell Death Dis

EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. [Abstract]

2025 Jul 14;16(1):522. PMID: 40659662
EBioMedicine

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma. [Abstract]

2023 Jan:87:104420. PMID: 36592514
EBioMedicine

The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia. [Abstract]

2018 Aug:34:61-75. PMID: 30072211
J Transl Med

Acetylation suppresses breast cancer progression by sustaining CLYBL stability. [Abstract]

2025 Apr 10;23(1):415. PMID: 40211376
Biochem Pharmacol

Direct reprogramming of human fibroblasts into hair-inducing dermal papilla cell-like cells by a single small molecule. [Abstract]

2025 Jan 9:116744. PMID: 39798934
Cancer Immunol Immunother

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. [Abstract]

2023 Jul;72(7):2331-2346. PMID: 36932256
Eur J Pharmacol

Low-dose treatment with Epirubicin, a novel histone deacetylase 1 inhibitor, exerts anti-leukemic effects by inducing ferroptosis. [Abstract]

2024 Dec 15:985:177058. PMID: 39413949
Clin Epigenetics

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression. [Abstract]

2022 Jul 7;14(1):84. PMID: 35799216
Biochim Biophys Acta Mol Basis Dis

INSR/AKT1 axis promotes cells proliferation and migration in acute myeloid leukemia. [Abstract]

2025 Dec 13;1872(3):168132. PMID: 41397617
J Mol Med

HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. [Abstract]

2021 Jan;99(1):107-118. PMID: 33128580
Biochim Biophys Acta Mol Basis Dis

A Trichostatin A (TSA)/Sp1-mediated mechanism for the regulation of SALL2 tumor suppressor in Jurkat T cells. [Abstract]

2018 May 18;S1874-9399(18)30028-2. PMID: 29778644
Sci Rep

A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice. [Abstract]

2026 Feb 8;16(1):7792. PMID: 41656387
Cancer Sci

Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K/AKT/mTOR Dephosphorylation. [Abstract]

2025 Sep 3. PMID: 40903394
Sci Rep

Upregulation of CD22 by Chidamide promotes CAR T cells functionality. [Abstract]

2021 Oct 19;11(1):20637. PMID: 34667217
J Cell Mol Med

HBI-8000 improves heart failure with preserved ejection fraction via the TGF-β1/MAPK signalling pathway. [Abstract]

2024 Apr;28(7):e18238. PMID: 38509729
iScience

Chidamide suppresses adipogenic differentiation of bone marrow derived mesenchymal stem cells via increasing REEP2 expression. [Abstract]

2023 Feb 16;26(3):106221. PMID: 36879811
Mol Carcinog

BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma. [Abstract]

2026 Jun;65(6):754-769. PMID: 41950351
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Biochem Biophys Rep

Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway. [Abstract]

2026 Jan 24:45:102469. PMID: 41631215
Biochem Biophys Res Commun

Chidamide induces cell cycle arrest via NR4A3/P21 axis upregulation to suppress relapsed and refractory acute myeloid leukemia. [Abstract]

2024 Aug 5:737:150493. PMID: 39133986
Leuk Lymphoma

RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo. [Abstract]

2022 May;63(5):1167-1179. PMID: 34865571
Authorea

2025 Apr 18.
Environ Toxicol

Metformin and chidamide synergistically suppress multiple myeloma progression and enhance lenalidomide/bortezomib sensitivity. [Abstract]

2024 Apr;39(4):2452-2465. PMID: 38251764
Research Square Print

2023 Mar 9.
Research Square Print

September 9th, 2022.
Research Square Print

August 18th, 2022.
Research Square Preprint

2022 May.
Research Square Preprint

2022 Feb.
Research Square Preprint

2021 Jul.
Biomed Pharmacother

miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. [Abstract]

2019 Nov;119:109413. PMID: 31518872

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (128.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 1 mg/mL (2.56 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5614 mL

12.8070 mL

25.6141 mL

5 mM

0.5123 mL

2.5614 mL

5.1228 mL

10 mM

0.2561 mL

1.2807 mL

2.5614 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (273 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Ning ZQ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.5614 mL	12.8070 mL	25.6141 mL	64.0352 mL
DMSO	5 mM	0.5123 mL	2.5614 mL	5.1228 mL	12.8070 mL
	10 mM	0.2561 mL	1.2807 mL	2.5614 mL	6.4035 mL
	15 mM	0.1708 mL	0.8538 mL	1.7076 mL	4.2690 mL
	20 mM	0.1281 mL	0.6404 mL	1.2807 mL	3.2018 mL
	25 mM	0.1025 mL	0.5123 mL	1.0246 mL	2.5614 mL
	30 mM	0.0854 mL	0.4269 mL	0.8538 mL	2.1345 mL
	40 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6009 mL
	50 mM	0.0512 mL	0.2561 mL	0.5123 mL	1.2807 mL
	60 mM	0.0427 mL	0.2135 mL	0.4269 mL	1.0673 mL
	80 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8004 mL
	100 mM	0.0256 mL	0.1281 mL	0.2561 mL	0.6404 mL

Keywords

Tucidinostat

36 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Tucidinostat

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Liver Cancer Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Cysteine Targeted Covalent Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Tucidinostat

Ver todos los productos específicos de isoformas HDAC

Actividad biológica

Chemical Information

Publications (36)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Tucidinostat Related Classifications

HY-109015 Related Classifications